$MIRM News

Citigroup Initiates Coverage On Mirum Pharmaceuticals with Buy Rating, Announces Price Target of $145

Wolfe Research Initiates Coverage On Mirum Pharmaceuticals with Outperform Rating, Announces Price Target of $145

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mirum Pharmaceuticals Prices $600.0 Million Convertible Senior Notes Offering; Refinances a Portion of 2029 Convertible Notes

Mirum Pharmaceuticals Announces Proposed Convertible Senior Notes Offering

Mirum Pharmaceuticals Announces Proposed $600M Offering Of Notes Due 2032

Mirum Pharmaceuticals: A Rare Disease Platform Becoming Bigger Than Its First Franchise

Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences

Mirum Pharmaceuticals (MIRM) Is Up 16.9% After Volixibat Phase 2b PSC Itch Data And Big Q1 Loss - Has The Bull Case Changed?

TD Cowen Maintains Buy on Mirum Pharmaceuticals, Raises Price Target to $145

RBC Capital Maintains Outperform on Mirum Pharmaceuticals, Raises Price Target to $142

Evercore ISI Group Maintains Outperform on Mirum Pharmaceuticals, Raises Price Target to $138

Baird Maintains Outperform on Mirum Pharmaceuticals, Raises Price Target to $129

Mirum Pharmaceuticals Q1 Earnings Call Highlights

Mirum Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary

Mirum Pharmaceuticals, Inc. (MIRM) Q1 2026 Earnings Call Transcript

Here's What Key Metrics Tell Us About Mirum Pharmaceuticals (MIRM) Q1 Earnings

Mirum (MIRM) Q1 2026 Earnings Call Transcript

Mirum Pharmaceuticals (NASDAQ:MIRM) Stock Dips After Q1 Revenue Beat and Guidance Raise, Despite Massive IPR&D Charge

Mirum Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update